PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment.

Journal: British journal of cancer
Published Date: Aug 20, 2025

Abstract

BACKGROUND: Practice guidelines recommend panitumumab with chemotherapy to treat KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. However, not all patients respond to this therapy. We propose a score termed "PROCC" to identify likely panitumumab responders.

Authors

  • Carlos María Galmarini
    R&D Department, Topazium Artificial Intelligence, Calle Bahía de Pollensa 5, 28042, Madrid, Comunidad de Madrid, Spain. cmgalmarini@topazium.com.
  • Rafael Zamora
    Medicus, Larrea 877, C1117, Ciudad Autónoma de Buenos Aires, Argentina.
  • Pablo Gómez Del Campo
    Topazium Artificial Intelligence, Madrid, Spain.
  • José Del Castillo-Izquierdo
    Topazium Artificial Intelligence, Madrid, Spain.
  • José Antonio De All
    Medicus, Larrea 877, C1117, Ciudad Autónoma de Buenos Aires, Argentina.
  • Juan Manuel Domínguez
    Topazium Artificial Intelligence, Madrid, Spain.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals